March 15, 2016 / 11:28 AM / a year ago

Orexigen buys U.S. rights to obesity drug from Takeda

1 Min Read

March 15 (Reuters) - Orexigen Therapeutics Inc said it would pay $60 million to acquire the U.S. rights to its flagship obesity drug from partner Takeda Pharmaceutical Co .

Orexigen said it had also entered into a deal with Canada's Valeant Pharmaceuticals International Inc to sell the treatment in central and eastern Europe. (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below